<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Public Health Rep</journal-id><journal-id journal-id-type="iso-abbrev">Public Health Rep</journal-id><journal-id journal-id-type="pmc-domain-id">333</journal-id><journal-id journal-id-type="pmc-domain">pubhealthrep</journal-id><journal-id journal-id-type="publisher-id">PHR</journal-id><journal-title-group><journal-title>Public Health Reports</journal-title></journal-title-group><issn pub-type="ppub">0033-3549</issn><issn pub-type="epub">1468-2877</issn><publisher><publisher-name>SAGE Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10240896</article-id><article-id pub-id-type="pmcid-ver">PMC10240896.1</article-id><article-id pub-id-type="pmcaid">10240896</article-id><article-id pub-id-type="pmcaiid">10240896</article-id><article-id pub-id-type="pmid">35674245</article-id><article-id pub-id-type="doi">10.1177/00333549221099323</article-id><article-id pub-id-type="publisher-id">10.1177_00333549221099323</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Sustained Virologic Response Rates Before and After Removal of Sobriety Restriction for Hepatitis C Virus Treatment Access</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3960-5616</contrib-id><name name-style="western"><surname>Martin</surname><given-names initials="MT">Michelle T.</given-names></name><degrees>PharmD</degrees><xref rid="aff1-00333549221099323" ref-type="aff">1</xref><xref rid="aff2-00333549221099323" ref-type="aff">2</xref><xref rid="corresp1-00333549221099323" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Waring</surname><given-names initials="N">Nicole</given-names></name><degrees>PharmD</degrees><xref rid="aff1-00333549221099323" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Forrest</surname><given-names initials="J">Jasmine</given-names></name><degrees>PharmD</degrees><xref rid="aff1-00333549221099323" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nazari</surname><given-names initials="JL">Jonathan L.</given-names></name><degrees>PharmD</degrees><xref rid="aff1-00333549221099323" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdelaziz</surname><given-names initials="AI">Abdullah I.</given-names></name><degrees>BPharm</degrees><xref rid="aff1-00333549221099323" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="TA">Todd A.</given-names></name><degrees>PharmD, PhD</degrees><xref rid="aff1-00333549221099323" ref-type="aff">1</xref></contrib></contrib-group><aff id="aff1-00333549221099323"><label>1</label>University of Illinois at Chicago College of Pharmacy, Chicago, IL, USA</aff><aff id="aff2-00333549221099323"><label>2</label>University of Illinois Hospital and Health Sciences System, Chicago, IL, USA</aff><author-notes><corresp id="corresp1-00333549221099323">Michelle T. Martin, PharmD, University of Illinois Hospital and Health Sciences System, University of Illinois at Chicago College of Pharmacy, 833 South Wood St, Ste 164, M/C 886, Chicago, IL 60612, USA. Email: <email>mmichell@uic.edu</email></corresp><fn fn-type="COI-statement"><p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.M. serves on the speakers&#8217; bureau for AbbVie and Gilead, has received grant funding from Gilead and Merck, served on the advisory board for AbbVie and Gilead, and is a minor shareholder of AbbVie, Gilead, and Merck stock. T.L. has received grant funding from Gilead, the Centers for Disease Control and Prevention, and the Illinois Department of Public Health; has served as an expert witness for Astra Zeneca; and has served as a consultant for Merck Serano.</p></fn></author-notes><pub-date pub-type="epub"><day>8</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="collection"><season>May-Jun</season><year>2023</year></pub-date><volume>138</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">437417</issue-id><fpage>467</fpage><lpage>474</lpage><pub-history><event event-type="pmc-release"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>01</day><month>05</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-01 00:25:16.013"><day>01</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2022, Association of Schools and Programs of Public Health</copyright-statement><copyright-year>2022</copyright-year><copyright-holder content-type="sage">US Surgeon General&#8217;s Office</copyright-holder></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10.1177_00333549221099323.pdf"/><abstract><sec id="section1-00333549221099323"><title>Objectives:</title><p>Until November 1, 2018, Illinois Medicaid restricted coverage of hepatitis C virus (HCV) medication to patients with sobriety from alcohol and illicit substances for &#8805;12 months. This policy limited treatment access for patients with a high risk of HCV transmission, despite clinical trial and real-world data demonstrating high sustained virologic response (SVR) rates among patients with substance use. The objective of this study was to compare HCV SVR rates between patients treated before and after removal of the Illinois Medicaid sobriety restriction.</p></sec><sec id="section2-00333549221099323"><title>Methods:</title><p>We performed a retrospective cohort study of Medicaid-insured patients who completed direct-acting antiviral treatment at an urban, academic medical center in Illinois from January 1, 2014, through October 21, 2020. The primary endpoint was SVR. We compared group characteristics using &#967;<sup>2</sup> or Fisher exact tests for categorical variables and Wilcoxon rank-sum tests for continuous variables. We used logistic regression to compare SVR rates before and after the policy change, adjusting for differences between groups.</p></sec><sec id="section3-00333549221099323"><title>Results:</title><p>A total of 496 patients (348 pre&#8211;policy change; 148 post&#8211;policy change) started treatment; excluding loss to follow-up/early discontinuation, SVR rates were 95.4% (309 of 324) pre&#8211;policy change and 97.1% (134 of 138) post&#8211;policy change. SVR rates did not differ after adjusting for the use of historic HCV regimens and the higher cirrhosis rate in the pre&#8211;policy change group compared with the post&#8211;policy change group (odds ratio = 0.98; 95% CI, 0.32-3.67).</p></sec><sec id="section4-00333549221099323"><title>Conclusion:</title><p>HCV SVR rates were similar before and after removal of the Illinois Medicaid sobriety restriction, regardless of group differences. Results support HCV treatment regardless of documented sobriety to facilitate progress toward HCV elimination.</p></sec></abstract><kwd-group><kwd>hepatitis C virus elimination</kwd><kwd>Medicaid policy</kwd><kwd>substance use</kwd><kwd>people who inject drugs</kwd><kwd>medications for opioid use disorder</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May/June 2023</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>